Study Supports Development Potential in Several Therapeutic Areas
Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders.
The findings, "Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation," appear in the March 2004 issue of Pharmacological Reviews, a publication of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
"MCR activation causes a collective reduction of the major molecules involved in the inflammatory process," said Anna Catania, M.D., professor of endocrinology, School of Internal Medicine, University of Milan and lead author of the study. "This discovery is significant because it shows that treatment with melanocortin peptides doesnt abolish the inflammatory response but instead modulates it. An advantage of melanocortins in the treatment of inflammation is that their influences are broad and are not restricted to a specific mediator or chemical pathway."
Recognition and cloning of five melanocortin receptors has greatly improved understanding of peptide-target cell interactions. Preclinical investigations indicate that activation of certain MCR subtypes, primarily MC1R and MC3R, could be useful in treatment of localized and systemic inflammatory disorders. These include: organ transplantation, chronic inflammatory diseases, acute inflammation, inflammation within the brain and neurogenerative disorders, peripheral neuropathies, systemic host reactions, ischemia and reperfusion injury and infections.
"The study results also indicate that certain melanocortin peptides have antimicrobial effects," said James Lipton, Ph.D., chief scientific officer and director of Zengen and study author. "Unlike corticosteroids, melanocortins do not reduce microbial killing activity, but enhance it. We are encouraged by these findings and will continue our research and development efforts in peptide technology."
Zengens researchers also conducted a separate study on melanocortin receptors that was published in the February 2004 issue of the Journal of Leukocyte Biology. The study, titled, "Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma," showed that activation of express melanocortin 1 receptor (MC1R) by selective peptides or peptidomimetics might provide a novel strategy to reduce mesothelioma cell proliferation by taking advantage of an endogenous inhibitory circuit based on alpha-Melanocyte-Stimulating Hormone ((-MSH), and its receptor MC1R.
About Zengen, Inc.
Founded in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Companys proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. For more information about Zengen, please visit www.zengen.com.
Kumiko Hakushi | Ruder Finn, Inc.
Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine